Denufosol

IUPAC: 2'- deoxycytidine (5 ') tetraphospho (5') uridine

R07AX

P2Y2 receptor agonist

Template: Infobox chemical / molecular formula search available

Not yet approved drug denufosol ( tetrasodium ) ( INS37217 ) is a P2Y2 receptor agonist to the inhalation of an alternative chloride channel is activated in the epithelial cells of the lung, so that the disease cystic fibrosis disturbed by the defective CFTR channel salt and water transportation is at least partially corrected. Thereby, the dehydrated liquid film is normalized, the ciliary beat frequency is increased, and the mucociliary clearance ( removal of the mucus by the cilia ) is improved. Denufosol should influence especially in the early stages of lung involvement the course positively. There have been several phase 3 trials conducted, the good, some did not yield statistically significant results for the part. The development was funded by the U.S. Cystic Fibrosis Foundation. Analysis of the same substance for the treatment of diseases of the retina were abandoned in 2006.